A review of drug treatments for systolic heart failure, highlighting its poor prognosis and significant healthcare burden.
Answers are grounded in this paper and cite their sources.
Reinforces high morbidity and costs in systolic HF; leaves open which regimens best improve outcomes.
Heart failure represents a complex clinical syndrome characterised by abnormalities of left ventricular function and neurohormonal regulation, exercise intolerance, shortness of breath, fluid retention, and reduced longevity. 1 Despite improvements in treatment the prognosis for patients with heart failure remains poor: the risk of death annually is 5%-10% in patients with mild symptoms and 30%-40% in those with advanced disease. 2 3 This condition is also associated with major morbidity and healthcare expenditure, being responsible for about 5% of hospital admissions in the United Kingdom. Non-pharmacological measures apply to all patients, whereas surgical and device treatments (many still experimental) apply only to specific patient subsets. Patients with clinical symptoms of heart failure but normal or near normal left ventricular systolic function often have impaired left ventricular diastolic function. This heterogeneous group has been generally excluded from heart failure trials. We do not discuss the treatment of diastolic left ventricular dysfunction or acute heart failure syndromes: more comprehensive reviews are available. 5
No takes yet. Share an insight, caveat, or question.
A 1990 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: